Valuation: Incyte Corporation

Market Cap 26.34B 23.14B 21.6B 19.82B 37.11B 2,523B 38.02B 256B 100B 1,248B 98.88B 96.73B 4,315B P/E 2026 *
57.8x
P/E 2027 * 17.1x
Enterprise Value 21.79B 19.14B 17.87B 16.4B 30.7B 2,087B 31.45B 212B 82.86B 1,033B 81.79B 80.02B 3,570B EV / Sales 2026 *
3.67x
EV / Sales 2027 * 3.26x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day-2.76%
1 week+8.84%
Current month+11.18%
1 month+9.92%
3 months+27.17%
6 months+24.68%
Current year+27.60%
1 week 114.5
Extreme 114.505
132.6
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 73.8
Extreme 73.805
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
23/7/26 Free

Chief Technology Officer

15,425 0.0077%
23/7/26 Free

EVP, Head of Incyte Intl

28,921 0.0145%
16/7/26 Free

Chairperson

104,772 0.0524%
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%+8.84%+62.88%+97.79% 25.96B
-0.02%+6.86%+24.67%-6.21% 70.73B
+0.28%+3.12%+35.58%+211.60% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+7.15%+5.51%-52.67%-51.99% 39.94B
+2.49%+7.01%+65.44%-21.68% 30.36B
-2.50%-5.95%+67.22%-53.58% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-1.32%+1.89%+81.83%+140.57% 16.77B
+1.37%+2.16%+67.45%+129.71% 16.72B
Average -0.00%+1.84%+39.58%+63.92% 34.61B
Weighted average by Cap. +0.07%+2.42%+33.08%+56.18%

Financials

2026 *2027 *
Net sales 5.94B 5.22B 4.87B 4.47B 8.37B 569B 8.58B 57.79B 22.6B 282B 22.31B 21.82B 974B 6.25B 5.49B 5.12B 4.7B 8.8B 598B 9.02B 60.77B 23.77B 296B 23.46B 22.95B 1,024B
Net income 469M 412M 385M 353M 661M 44.92B 677M 4.56B 1.78B 22.23B 1.76B 1.72B 76.85B 1.55B 1.36B 1.27B 1.16B 2.18B 148B 2.23B 15.03B 5.88B 73.23B 5.8B 5.68B 253B
Net Debt -4.55B -4B -3.73B -3.43B -6.41B -436B -6.57B -44.26B -17.31B -216B -17.09B -16.72B -746B -5.97B -5.25B -4.9B -4.5B -8.41B -572B -8.62B -58.08B -22.71B -283B -22.42B -21.93B -979B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
30/07/26 USD 126.01 -3.02% 906,398
28/07/26 USD 129.93 +9.30% 5,921,515
27/07/26 USD 118.87 +1.02% 2,729,176
24/07/26 USD 117.67 +0.84% 1,207,106
23/07/26 USD 116.69 +0.78% 956,259
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
129.93USD
Average target price
121.27USD
Spread / Average Target
-6.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock